Showing 221-230 of 328 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| A Cure for Type 1 Diabetes | University of Massachusetts Medical School | David Harlan | Cures | 01-October-2022 to 30-September-2025 | $12.998.645,40 |
| JDRF-IQVIA Adult T1D Detection | IQVIA, Inc. | Nadejda Leavitt | Cures | 01-October-2022 to 31-August-2025 | $953.780,00 |
| Enabling studies to advance intra-lymph node depots as a durable antigen-specific immunotherapy for T1D | University of Maryland | Christopher Jewell | Cures | 01-February-2023 to 31-January-2026 | $989.997,00 |
| Engineered Nanoparticles for Beta Cell-Targeted Therapeutics | The University of Chicago | Raghavendra Mirmira | Cures | 01-April-2023 to 31-March-2026 | $897.822,00 |
| Type 1 Diabetes Consortium – New Onset Workstream | Critical Path Institute (C-Path) | Joseph Hedrick | Cures | 28-October-2022 to 31-December-2025 | $1.132.723,00 |
| Determination of autoreactive B lymphocyte development by ROS in T1D | Vanderbilt University Medical Center (VUMC) | Christopher Wilson | Cures | 01-July-2023 to 30-June-2026 | $234.766,00 |
| Tolerance signals from human pregnancy for beta cell replacement therapy | University of Florida | Edward Phelps | Cures | 01-December-2023 to 30-November-2025 | $600.000,00 |
| Development and Preclinical Assessment of a Biovascular Pancreas | Humacyte | Kaleb Naegeli | Cures | 01-April-2023 to 28-February-2027 | $863.333,00 |
| Transcriptional modulation by BET bromodomain inhibitors in beta cells | The Medical College of Wisconsin Inc. | Joshua Nord | Cures | 01-March-2023 to 28-February-2026 | $221.638,00 |
| Novel insulin formulations for pumps | Stanford University | Yanxian Zhang | Improving Lives | 01-March-2023 to 28-February-2026 | $243.986,00 |